Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana M Gonzalez-Angulo

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Cancer|September 29, 2011
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancerSoley Bayraktar, Ana M Gonzalez-Angulo, Xiudong Lei, et al.
Head & Neck|March 4, 2014
Phase II study of gefitinib in patients with advanced salivary gland cancersJohn A Jakob, Merrill S Kies, Bonnie S Glisson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancerAbigail S Caudle, Ana M Gonzalez-Angulo, Kelly K Hunt, et al.
Cancer|June 26, 2007
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissectionRosa F Hwang, Ana M Gonzalez-Angulo, Min Yi, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
Phase II trial of 10-EDAM in the treatment of metastatic breast cancerGarth A Beinart, Ana M Gonzalez-Angulo, Kristine Broglio, et al.
The Oncologist|February 5, 2008
Prognostic value of initial clinical disease stage after achieving pathological complete responseShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerFrancisco J Esteva, Stacy L Moulder, Ana M Gonzalez-Angulo, et al.
Cancer Letters|May 8, 2025
ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacyShuying Liu, Huiqin Chen, Mihai Gagea, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2010
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancerJeffrey M Albert, Ana M Gonzalez-Angulo, Merih Guray, et al.
Cancer Research|August 15, 2008
Staging of breast cancer in the neoadjuvant settingJacqueline S Jeruss, Elizabeth A Mittendorf, Susan L Tucker, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Cancer|September 29, 2011
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancerSoley Bayraktar, Ana M Gonzalez-Angulo, Xiudong Lei, et al.
Head & Neck|March 4, 2014
Phase II study of gefitinib in patients with advanced salivary gland cancersJohn A Jakob, Merrill S Kies, Bonnie S Glisson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancerAbigail S Caudle, Ana M Gonzalez-Angulo, Kelly K Hunt, et al.
Cancer|June 26, 2007
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissectionRosa F Hwang, Ana M Gonzalez-Angulo, Min Yi, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
Phase II trial of 10-EDAM in the treatment of metastatic breast cancerGarth A Beinart, Ana M Gonzalez-Angulo, Kristine Broglio, et al.
The Oncologist|February 5, 2008
Prognostic value of initial clinical disease stage after achieving pathological complete responseShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerFrancisco J Esteva, Stacy L Moulder, Ana M Gonzalez-Angulo, et al.
Cancer Letters|May 8, 2025
ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacyShuying Liu, Huiqin Chen, Mihai Gagea, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2010
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancerJeffrey M Albert, Ana M Gonzalez-Angulo, Merih Guray, et al.
Cancer Research|August 15, 2008
Staging of breast cancer in the neoadjuvant settingJacqueline S Jeruss, Elizabeth A Mittendorf, Susan L Tucker, et al.
Pageof 15